SQUAMOUS NON-SMALL-CELL LUNG CANCER
Clinical trials for SQUAMOUS NON-SMALL-CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new SQUAMOUS NON-SMALL-CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for SQUAMOUS NON-SMALL-CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cocktail of immune drugs shows promise in lung cancer trial
Disease control CompletedThis phase 2 study tested three different drug combinations in 151 people with advanced non-small cell lung cancer that had not been treated before. The drugs help the immune system attack cancer cells. Researchers measured how many patients' tumors shrank or stopped growing, and…
Matched conditions: SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug, TAK-981, combined with the immunotherapy pembrolizumab in 161 adults with advanced or metastatic solid tumors that could not be cured. The main goals were to check safety and see if the combination could shrink tumors. Participants received treatment…
Matched conditions: SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New immunotherapy DF9001 targets Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called DF9001, which helps the body's natural killer cells attack cancer cells. It was given alone or with another immunotherapy (pembrolizumab) to 24 adults with advanced solid tumors that have the EGFR protein. The goal was to check safety and find …
Matched conditions: SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC